Methotrexate (MTX) is often the first drug prescribed to patients diagnosed with rheumatoid arthritis (RA), but the response to it is highly variable. Both genetic and environmental factors determine whether the drug will be effective or cause adverse side effects. However, known factors explain only a small proportion of observed variability, and nobody has yet investigated on how obesity modifies the effect of the genes on MTX response in RA.